News
Google News
More headlines & perspectives

Eli Lilly shares rise following positive weight-loss drug trials

Top news

Reuters

Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

By Mrinalika Roy & Shinjini Ganguli
WSJ

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

By Joe Stonor
Yahoo Finance

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

investor.lilly.com

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

Fierce Biotech

ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

By Fraiser Kansteiner

All coverage

Barron's

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

By Mackenzie Tatananni & Callum Keown
The Guardian

Triple-action diabetes jab shown to reduce blood sugar and body weight

By Anna Bawden
Bloomberg

Lilly’s 30% Weight Loss Sets High Bar for Obesity Drug Race

By Naomi Kresge & Madison Muller
Medscape

Retatrutide Data Show Dramatic Weight Loss, Other Benefits

By Miriam E. Tucker
statnews.com

Lilly shares safety, tolerability data on its next-gen obesity drug

By Elaine Chen
Fierce Pharma

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

By Kevin Dunleavy
MedPage Today

'Bariatric Surgery-Level' Weight Loss With Novel Triple-Agonist

By Kristen Monaco
qz.com

Eli Lilly stock jumps on retatrutide Phase 3 weight loss results

BioSpace

ADA: Lilly’s weight loss mastery shows benefits in menopause, sleep apnea, more

By Annalee Armstrong
MarketWatch

Eli Lilly stock rises after late-stage trial of next-generation weight-loss drug

By Steve Goldstein
CNBC

Eli Lilly CEO: Retatrutide will help those with BMI over 40 get to a healthy weight

Everyday Health

Is Retatrutide Too Strong? What to Know About This Powerful New Drug

By Korin Miller
HCPLive

Orforglipron Delivers Significant Weight Loss At Every Stage of Menopause in Phase 3 ATTAIN Trials

By Abigail Brooks
Hospital Healthcare Europe

Retatrutide yields results similar to bariatric surgery, phase 3 trial finds

By Helena Beer
Moomoo

Tired of Nausea or Taking a GLP-1 Pill Every Day? These Experimental Drugs Could Be Better Than Zepbound and Wegovy.

By Jaimy Lee
pharmaphorum

ADA: Lilly's weight-loss reveal, and wannabes display wares

Patient Care Online

Retatrutide Phase 3 Data Show Weight, A1C Reductions in Obesity and Type 2 Diabetes

By Sydney Jennings
The Clinical Trial Vanguard

Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial

By Jon Napitupulu
PR Newswire

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Mint

A weight-loss drug that also controls sleep apnea and knee pain: Eli Lilly may have found one

AOL.com

Why Eli Lilly Stock Climbed to a New All-Time High Today

By Joe Tenebruso
Investor's Business Daily

Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'

By Allison Gatlin
Forbes

Retatrutide vs. Semaglutide for Weight Loss—What’s the Difference?

By Jessica Rendall
The Globe and Mail

Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better

Stocktwits

LLY Stock Heads To Record High – Here’s Why Retail’s Bullish On Latest GLP-1 Data

By Arnab Paul
simplywall.st

Will Menopause Data and Coverage Wins Recast Eli Lilly’s (LLY) Obesity-Care Narrative?

Managed Healthcare Executive

Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026

By Rose Mcnulty
TradingKey

Eli Lilly and Co Stock (LLY) Moved Up by 3.37% on Jun 8: What Signal Does It Send?

Traders Union

Weight-loss drug updates at diabetes conference propel Eli Lilly stock higher

By Emilio Ghigini
GuruFocus

Eli Lilly's Retatrutide Shows Promising Results in Obesity Treat

MSN

Lilly's powerful new weight loss drug impresses while other experimental shots struggle

Health: Trusted and Empathetic Health and Wellness Information

An Experimental Weight Loss Drug Could Outperform Ozempic. Here’s What Makes It Different.

By Allison Forsyth
medwatch.com

Eli Lilly demonstrates significant weight loss and health benefits in phase 3 trial of weight-loss candidate

Benzinga

Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages

By Vandana Singh
Pharmacy Times

What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results

By Jennifer L Goldman & Luke Halpern
Reuters

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

By Caroline Humer, Chris Prentice & Will Dunham
Yahoo Finance

Eli Lilly stock jumps on retatrutide Phase 3 weight loss results

Yahoo Finance

Eli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story

Yahoo Finance

Eli Lilly shares climb after new obesity drug results impress at ADA conference (LLY)

By Fiona Craig
MarketWatch

A new wave of weight-loss therapies aims to be better than today’s GLP-1s

By Jaimy Lee
The Motley Fool

Why Eli Lilly Stock Climbed to a New All-Time High Today

By Joe Tenebruso
Seeking Alpha

Eli Lilly reports broad benefits for experimental obesity drug retatrutide (LLY:NYSE)

By Rob Williams
TipRanks

‘This Is Compelling’: Citi Pounds the Table on Eli Lilly (LLY) Stock

By Marty Shtrubel
TipRanks

Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story

By Ran Melamed
The Economic Times

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

MedPage Today

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

By Kristen Monaco
Investing.com Australia

Bernstein reiterates Eli Lilly stock rating on obesity drug data By Investing.com

The Eastleigh Voice

New weekly triple-action diabetes injection linked to significant weight loss and better health

Indian Pharma Post

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

Search
Clear search
Close search
Google apps
Main menu